Aethlon Medical (AEMD) vs Cytosorbents (CTSO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cytosorbents is the larger company by market cap ($11.8 million vs $9.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AEMD | CTSO |
|---|---|---|
| Share price | $6.01 | $3.73 |
| Market cap | $9.64M | $11.75M |
| 1-day change | -0.99% | -3.62% |
| YTD return | — | -70.81% |
| 1-year return | — | -80.87% |
| 5-year return | — | -96.82% |
| EPS (TTM) | $-32.97 | $-5.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $37.00 | $19.72 |
| 52-week low | $1.41 | $3.66 |
| Distance from 52-week high | -83.76% | -81.09% |
| Analyst consensus | none | none |
| Avg. price target upside | +120.47% | +1173.46% |
| Average volume | 2.56M | 12.45K |
| Shares outstanding | 1.60M | 3.15M |
| Employees | 9 | 129 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aethlon Medical
AEMD stock →Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states.
Healthcare · Medical Devices · 9 employees
About Cytosorbents
CTSO stock →Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.
Healthcare · Medical Devices · 129 employees
AEMD vs CTSO FAQ
Which is bigger, Aethlon Medical or Cytosorbents?
Cytosorbents (CTSO) is larger, with a market capitalization of $11.75M compared with $9.64M for Aethlon Medical (AEMD).
Are Aethlon Medical and Cytosorbents in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.